Skip to main content
. 2016 May 12;13(6):424–431. doi: 10.7150/ijms.14475

Table 3.

Percentage of distribution for HPV16 IgG and HPV16 IgM among the OSCC patients and the control group

OSCC Samples
(n=206)
Control Samples
(n=134)
No. of Patients % No. of Patients %
HPV16 IgG
Positive 197 95.6 89 66.4
Negative 9 4.4 45 33.6
HPV16 IgM
Positive 42 20.4 0 0
Negative 164 79.6 134 100